Resource library

Presentations

Videos

Featured
Don't F*** with the Density of Ice
Don't F*** with the Density of Ice
The Investor’s Paradox
The Investor’s Paradox
Affordability & Innovation
Affordability & Innovation
Inventing new medicines is a long climb
Inventing new medicines is a long climb
IRA Webinar: Impact of the Inflation Reduction Act for Biotech Builders… and (how) can it be fixed?
IRA Webinar: Impact of the Inflation Reduction Act for Biotech Builders… and (how) can it be fixed?
What is Abbie Saving For?
What is Abbie Saving For?
The Failure to Communicate Value
The Failure to Communicate Value
The Value of Medicines
The Value of Medicines

Research

Letters & Public Comments

Media

Featured
The Evidence Base: New framework proposed for valuing medicines’ broader societal impact
The Evidence Base: New framework proposed for valuing medicines’ broader societal impact
R&D World: How much does the pharma industry spend on R&D anyway? Probably more than you thought
R&D World: How much does the pharma industry spend on R&D anyway? Probably more than you thought
USA Today: Mammograms can prevent breast cancer deaths. But many skip screening due to cost.
USA Today: Mammograms can prevent breast cancer deaths. But many skip screening due to cost.
Cambridge Day: Health care costs keep rising, but biopharma is not the enemy
Cambridge Day: Health care costs keep rising, but biopharma is not the enemy
AI can make it easier to discover new medicines – but Congress is making it harder
AI can make it easier to discover new medicines – but Congress is making it harder
STAT News: The world is relying on the United States to get value-based drug pricing right
STAT News: The world is relying on the United States to get value-based drug pricing right
5 ways Biden’s SOTU could advance biotech affordability and innovation
5 ways Biden’s SOTU could advance biotech affordability and innovation
Bucks County Herald: Drug price controls hurt investment in new medicines
Bucks County Herald: Drug price controls hurt investment in new medicines
Fairfax Connection: Our Neighborhood’s Special Role in Saving Babies from Norovirus</a>
Fairfax Connection: Our Neighborhood’s Special Role in Saving Babies from Norovirus
The Well News: Ensuring Medicare Rx Price Negotiations Help Patients
The Well News: Ensuring Medicare Rx Price Negotiations Help Patients
Xtelligent Healthcare: The Importance of Accurately Measuring the Value of New Medications
Xtelligent Healthcare: The Importance of Accurately Measuring the Value of New Medications
PharmaExec: The Value of Care - Q&amp;A With Peter Rubin, Executive Director at No Patient Left Behind
PharmaExec: The Value of Care - Q&A With Peter Rubin, Executive Director at No Patient Left Behind
BioCentury: New cost-effectiveness model aims to better capture value of medicines to society
BioCentury: New cost-effectiveness model aims to better capture value of medicines to society
Measuring the damage: IRA’s impact on small molecule drug development
Measuring the damage: IRA’s impact on small molecule drug development

Op-eds and blog posts

Community Quests

Press Releases

Featured
New Paper: Leading Health Economists Explain How to Fix the Faulty & Outdated Models Used to Calculate the Value of Medicines
Getting the Math Right: The Growing Movement to Improve How Medicines Are Valued Will Take Center Stage at ISPOR 2024
APRIL FOOLS’: FTC Announces Zero Copay Mandate
Investors and Innovators Representing more than $309B in Biotech Assets and 624 New Drugs in Development Urge the Congressional Budget Office to Update its Drug R&D Policy Impact Model
Statement / Background Info Regarding the Institute for Clinical and Economic Review’s (ICER) Proposed Value Assessment Framework
Innovative Medicines Provide Greater Value to Patients and Society than Previously Calculated
NPLB Statement on ICER’s Flawed Value Assessment Framework
New NPLB Video Illustrates Why Patients Deserve Better Math to Value New Drugs
NPLB Gets Animated: Roadmap to Patient Affordability and Innovation
One Thousand Investors, Researchers, Patients, & Innovators Sign Letter Urging Critical Fixes to Senate Rx Bill
“Abbie” Video Highlights Need for Insurance Reforms that Lower Out-of-Pocket Costs
NPLB: CMS Rule to Lower Maximum Out-of-Pocket Costs by $400 Will Help Patients, More Reductions Needed
NPLB Applauds Growing Momentum for Insurance Reforms that Lower Out-of-Pocket Costs for Patients
American Rescue Plan Takes Important Action to Expand Affordable Health Coverage

We’re building support across the biotech ecosystem

BECOME A FIRST RESPONDER & THOUGHT PARTNER

Sign up to receive action alerts. Help protect access to lifesaving medicines & preserve innovation for those still waiting for a cure.